HANSHOW
27.3.2024 10:56:30 CET | Business Wire | Press release
From March 13th to 15th, the 24th China Retail Expo was held at Shanghai's National Convention and Exhibition Center. Under the theme "Green Digitalization and GenAI for Sustainable Retail," Hanshow debuted its pioneering GenAI product strategy, marking a significant leap forward in retail's AI era. The showcase included the upgraded Hanshow Polaris Pro series electronic shelf labels (ESL) and a new green digital store solution, reaffirming Hanshow's dedication to providing retailers with cutting-edge technologies for enhanced efficiency, improved shopper experiences, and sustainable practices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240320389359/en/
The breakthrough of Generative Pre-trained Transformer 3 (GPT-3) technology, represented by represented by ChatGPT, has expanded the boundaries of all industries. Hanshow is Microsoft’s global strategy partner in the retail industry since 2023 and is one of the first to incorporate GenAI technology in retail scenarios using Azure OpenAI (AOAI).
At the event, Eason Tong, Dean of the Hanshow Retail Research Institute, announced Hanshow's first GenAI solution for retail business operations based on strategic cooperation with Microsoft. For retailers, Hanshow uses OpenAI's large model capabilities integrated with massive digital retail data to create the industry's first automated content (copy + image) generation intelligent application solution - the Hanshow Store Marketing Assistant.
The GenAI solution released by Hanshow relies on open source GPT-4 text output and Dall-E3 image output and can generate commodity POP posters, marketing atmosphere posters, and product copy through dialogue interaction. The internal integration of Hanshow's product ecosystem allows the generated materials to be uploaded and shown on the Hanshow Lumina Screen and upcoming large-sized colorful electronic paper posters with one click.
With the Hanshow Store Marketing Assistant, stores can easily generate a variety of creatively designed marketing materials to vividly portray product selling points while controlling marketing costs and improving sales. Whether it is a store operator or a brand owner, retailers can use the solution to reduce creative work from several hours to a few minutes.
"Hanshow is dedicated to offering retailers a retail media network solution that diversifies income streams. Leveraging generative AI for content, personalization, and impact assessment, we support future store media networks comprehensively," said Tong.
Microsoft and its ecosystem have supported Hanshow in building a digital store solution based on Azure OpenAI capabilities, and the two parties are deepening their cooperation and accelerating the landing of generative AI in global physical retail scenarios.
Microsoft and Hanshow jointly held a high-level roundtable forum to explore revolutionary omnichannel GenAI retail applications and trends and the green development and digital transformation of the retail industry.
"GenAI's remarkable capabilities are revolutionizing various industries. We're delighted to see Hanshow, Microsoft's global strategic partner, leveraging Azure OpenAI technology to introduce generative AI into physical retail. As a pioneer in retail digitalization, Hanshow combines industry insights with GenAI to present innovative digital store solutions," stated Frank Kong, Microsoft China's General Manager of Retail Consumer Goods.
Coming up, Hanshow and Microsoft’s GenAI marketing solutions for consumers will also be unveiled at the NRF exhibition in Singapore in June 2024, covering the four areas of store operations, consumer experience, store media, and green energy.
About Hanshow
Hanshow is one of the global leaders in the development and manufacturing of electronic shelf labels and digital store solutions. The company offers customers a series of customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow's solutions have provided services to a vast number of stores across more than 50 countries and regions, helping them streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240320389359/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
Digital Reef Turns to Vertical Farming to Reduce Data Centre Footprint in Partnership With Elevate Farms and Xange.com to Provide Digital Measurement, Reporting and Verification of Project's Environmental Impact Within the Reef Origin Ecosystem23.10.2026 13:12:00 CEST | Press release
The collaboration leverages Elevate Farms’ proprietary vertical farming technology reducing water consumption, land usage and carbon emissions. Elevate Farms Inc. and Digital Reef Ltd partnership supports mitigating environmental impact of global data centre expansion establishing a framework for Digital Reef’s infrastructure pipeline to support and utilize environmental assets generated by Elevate Farms' high-yield, closed-loop vertical farming operations. Traditional agriculture supply chains are replaced with optimized indoor facilities significantly reducing food production carbon emissions, water waste and local land constraints. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022393352/en/ Elevate Farms technology offers part of the solution to climate impact isolating food production from traditional agricultural farming variables saving over 95% of standard water requirements and significantly reducing farmland req
SLB Announces Third-Quarter 2026 Results23.10.2026 12:50:00 CEST | Press release
Revenue of $9.45 billion increased 5% sequentially and 6% year on year GAAP EPS of $0.49 decreased 6% sequentially and 2% year on year EPS, excluding charges and credits, of $0.64 increased 16% sequentially and decreased 7% year on year Net income attributable to SLB of $735 million decreased 6% sequentially and 1% year on year Adjusted EBITDA of $2.07 billion increased 9% sequentially and was essentially flat year on year Cash flow from operations was $1.51 billion and free cash flow was $828 million Board approved quarterly cash dividend of $0.295 per share SLB (NYSE: SLB) today announced results for the third-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021694458/en/ The exterior of the SLB headquarters in Houston, Texas. Third-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2026Jun. 30, 2026Sept. 30, 2025SequentialYear-on-yearRevenue $9,449 $8,972 $8,928 5
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom